Effect of Irbesartan on Glucose Tolerance in a Type 2 Diabetes Mellitus Mouse Model by Mangoyi, Japhet & Khoza, Star
Mangoyi et al, Afr. J. Pharmacol. Ther. 2015. 4(4): 169-174 
 
A KeSoBAP Publication ©2015. All rights reserved.  ISSN 2303-9841 
169 
 
Effect of Irbesartan on Glucose Tolerance in a 
Type 2 Diabetes Mellitus Mouse Model 
Japhet Mangoyi a,*, and Star Khoza a 
 a Department of Clinical Pharmacology, College of Health Sciences, University of Zimbabwe 
 _____________ 
* Corresponding author: Department of Clinical Pharmacology, College of Health Sciences, P.O. Box A178, Avondale, 
Harare, Zimbabwe. Tel: +263 4 705581. Email: japhetmangoyi@gmail.com            
 
Background: Angiotensin receptor blockers (ARBs) have been reported to affect glycaemic control in both animals 
and humans. A few studies have evaluated the effects of irbesartan on blood glucose levels and ARBs are 
recommended in patients with comorbid diabetes and hypertension. However, the effect of irbesartan on insulin 
resistance and glucose tolerance is inconclusive and contradicting. 
Objectives: To evaluate the effect of irbesartan on blood glucose levels and glucose tolerance in diabetic and non-
diabetic mice.  
Materials and methods: Diabetes was induced in 18 obese BALB/c mice fed on high fat diet using alloxan 
monohydrate 150mg/kg via the intra-peritoneal route. Non-diabetic mice were assigned to three treatment groups 
(n=6/group) and each group received either of the following treatments: 20mg/kg irbesartan or 75mg/kg irbesartan 
or vehicle. Diabetic mice were also divided into three groups and each group received one of the three treatments 
mentioned above. Drug administration was done daily via oral gavage for 14 days. Blood glucose levels were 
measured on day 1 (baseline values), day 8, and day 13 of treatment.  An oral glucose tolerance test was carried out on 
day 14 after administration of 50% dextrose at the dose of 1g/kg body weight. Blood glucose levels at 15, 30, 60 and 
120 minutes were measured during the oral glucose tolerance test.  
Results: Irbesartan at the dose of 20mg/kg (-39.44% ±8.96, p=0.0177) and 75mg/kg (-40.07% ±6.27, p=0.0111) 
significantly lowered blood glucose levels in diabetic mice. However, irbesartan 20mg/kg (-14.87% ±10.13, p>0.9999) 
and 75mg/kg (-9.07%±3.77, p>0.9999) did not significantly change blood glucose levels in non-diabetic mice. In non-
diabetic mice there was only a modest difference in AUC in the irbesartan20mg/kg (AUC=28.73mmol/Lmin, 
p=0.6435), 75mg/kg (AUC=26.66mmol/Lmin, p>0.9999) compared to the non-diabetic control (AUC=26.63 
mmol/Lmins). Although there was a slight improvement in glucose tolerance in diabetic mice, irbesartan 20mg/kg 
(AUC=55.35mmol/Lmin, p>0.9999) and 75mg/kg (AUC=45.54mmol/Lmin, p=0.1737) had no significant effect on 
glucose tolerance compared to the diabetic control group (AUC=63.53mmol/Lmin). 
Conclusion:  At standard treatment doses, irbesartan had a significant hypoglycaemic effect without significantly 
improving glucose tolerance in diabetic mice.  
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1. Introduction 
Angiotensin converting enzyme (ACE) inhibitors and 
angiotensin receptor blockers (ARBs) are two major 
classes of drugs used in the management of 
hypertension that have similar efficacy(Strippoli et al., 
2006).Their renoprotective effects have been observed 
to be better than other classes of antihypertensive 
agents (Strippoli et al, 2006, Sarafidis et al, 2008, 
Strippoli et al, 2005). Recent evidence  suggests that the 
benefit of ARBs and ACEIs in patients with diabetes go 
beyond their renoprotective effects(Ram, 2011). They 
have been linked with positive glycaemic effects in 
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diabetic mellitus (Sica, 2002, ALLHAT, 2002, Hansson et 
al, 1999). 
Although ACEI and ARBs are now widely considered as 
hypoglycaemic in nature, there is conflicting evidence 
regarding their glycaemic effects. Some studies have 
reported no change in fasting blood glucose levels while 
other studies suggest that the hypoglycaemic effects are 
neither a class property nor dose-dependent (Negro et 
al, 2006, Benson et al, 2004, Munoz et al, 2009, 
Henriksen et al, 2001). In a study by Negro et al., 
telmisartan was observed to be superior to irbesartan 
in decreasing insulin resistance (Negro et al, 2006). 
Similarly, Benson et al., reported that telmisartan 
reduces fasting blood glucose levels (Benson et al, 
2004). Significant decreases in HbAlc and fasting 
plasma glucose (FPG) were also observed after 6 
months and 12 months treatment with telmisartan 
(Benson et al, 2004). However, Derosa et al., reported 
that 12 months treatment with irbesartan resulted in 
non-significant decreases in FPG and Hb1Ac (Derosa et 
al, 2006). Similarly, the study by Usuiet al., concluded 
that fasting plasma glucose and HbA1c were not 
affected by 6 months of treatment with telmisartan in 
diabetic patients (Usui et al, 2007). 
Experimental studies using animal models have also 
produced equivocal findings. In a study by Munoz et al., 
amelioration of insulin resistance in adipose tissue was 
observed in male obese Zucker rats (fa/fa) treated with 
50 mg/kg irbesartan for 6 months (Munoz et al, 2009). 
Similarly, angiotensin receptor blockade with 
olmesartan increased pancreatic insulin secretion and 
decreased glucose intolerance during glucose 
supplementation in a model of metabolic syndrome in 
rats(Rodriguez et al., 2012).In contrast, Aritomi et al., 
reported that use of valsartan alone did not cause a 
significant decrease in blood glucose levels in rats 
(Aritomi et al, 2012). However, in the same study 
significant hypoglycaemic effects were observed when 
valsartan was combined with cilnidipine (a calcium 
channel blocker) (Aritomi et al, 2012). 
Both clinical and animal studies conducted to date have 
provided inconsistent evidence regarding the glycaemic 
effects of angiotensin receptor blockers in patients with 
co-morbid hypertension and diabetes mellitus. 
Therefore, there is need for more experimental 
evidence regarding the glycaemic effects of angiotensin 
receptor blockers. Irbesartan is a potent and selective 
angiotensin II subtype 1 receptor antagonist indicated 
for use in patients with hypertension, including those 
with type 2 diabetes mellitus and nephropathy 
(Bramlage et al, 2009, Ruilope and Segura, 2003). The 
objective of this study was to evaluate the effect of 
irbesartan on blood glucose control and glucose 
tolerance in diabetic and non-diabetic mice models. 
2. Materials and Methods 
2.1 Materials  
Irbesartan tablets (Winthrop Pharmaceutics; Midrand, 
South Africa, Batch number: 3A699), normal saline, 5% 
dextrose, 50% dextrose, glucose monitoring machine kit 
where sourced from local suppliers. Standard normal 
mouse feed and high fat diet were obtained from a local 
stock feed manufacturer (National Foods Company of 
Zimbabwe). Alloxan monohydrate was purchased from 
Sigma Chemicals in Germany (Batch Number. 
BCBK4716V).  
2.2 Study design and induction of Type I diabetes 
Thirty six male BALB/c mice were purchased from a 
regulated breeder (Department of Veterinary Services, 
Ministry of Agriculture).  
The mice were divided into two broad experimental 
groups. One group was fed on a standard mice diet 
(n=18) and the other group (n=18) was fed on a high-fat 
diet. Both groups were fed for six weeks. This was done 
to ensure induction of obesity (and insulin resistance) 
in the high fat diet group (Panchal and Brown, 2011). 
Diabetes mellitus was  induced on 18 overnight-fasted 
obese mice using a single intraperitoneal injection of 
150 mg/kg body weight of alloxan monohydrate 
dissolved in 0.9% w/v saline solution(Shankar and 
Mehendale, 2005). The mice were given 5% glucose 
solution  for the three days post-diabetes induction to 
combat early phase hypoglycemia (Mishra A et al., 
2010).  
After three  days of the injection, blood samples were 
drawn from tail vein of overnight fasted animals and 
fasting glucose levels were determined to confirm the 
development of diabetes (i.e. above  7mmol/l) (WHO, 
2005). 
2.3 Drug Administration  
Non-diabetic mice were divided into three groups 
(n=6/group) with each group receiving one of the 
following treatments: 20mg/kg irbesartan or 75mg/kg 
irbesartan or vehicle (distilled water).  
Diabetic mice were also divided into three groups and 
each group was treated with one of the following 
treatments: 20mg/kg irbesartan or 75mg/kg irbesartan 
or vehicle. The treatments were administered daily via 
oral gavage for 14 days. Irbesartan tablets were crushed 
and suspended in distilled water every morning just 
before administration. Blood glucose levels were 
measured on day 1(baseline), day 8, and day 13 of 
irbesartan administration.     
2.4 Glucose tolerance test 
An Oral Glucose Tolerance Test (OGTT) was carried out 
on day 14 after commencing irbesartan dosing. 
Following an overnight fast, a glucose load was 
administered at a dose of 1g/kg and blood glucose 
levels were measured over a span of 2 hours (15 
minutes, 30 minutes, one hour and 2 hours). A dose of 
1g/kg of glucose was chosen because in higher doses 
(>2g/kg) the amount of glucose to which the lean tissue 
is exposed in an obese mouse will be disproportionately 
high compared with that in a non-obese mouse with 
similar lean mass thus obese mice could be 
misdiagnosed as being glucose intolerant simply 
because they receive more glucose for the same lean 
body mass (Andrikopoulos et al., 2008). Measurement 
of blood glucose was done using an SD CodeFreeTM 
Blood Glucose Meter (SD Biosensor, Inc Korea). The 
meter uses the glucose oxidase method to determine 
glucose levels. 
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2.5 Statistical Analysis 
GraphPad® Prism Version 6.0 (California, USA) 
software was used for data analysis. Blood glucose 
levels and area under the curves (AUCs) were compared 
across the treatment groups using one away ANOVA. 
AUC is a measure of glucose exposure or rate of glucose 
utilisation. A high value of AUC represents poor glucose 
control. AUC was determined by the trapezoidal rule (a 
numerical integration method used to approximate the 
integral or the AUC) using GraphPad® Prism Version 
6.0 (Shi-Tao. et al, 1991). Where there was statistical 
significant difference, Bonferonni post-hoc test was 
used during paired comparisons. The significance level 
was set at α=0.05. 
2.6 Ethical considerations 
The study was approved by the Joint Parirenyatwa 
Hospital and College of Health Sciences Research 
Committee (JREC), University of Zimbabwe (approval 
number: JREC/125/14). Animals were handled 
following the principles outlined in the Zimbabwe 
Animal Experimentation Act of 1963. 
3.  Results  
Table 1 shows the actual blood glucose levels recorded 
at baseline, on day 8, and day 13 of treatment in both 
diabetic and non-diabetic mice. 
    Table 1: Actual blood glucose levels before the dosing on specific days 
Experimental group  
Baseline (day 1) (mmol/L) 
Mean±SEM 
Day 8 (mmol/L) 
Mean±SEM 
Day 13 (mmol/L) 
Mean±SEM 
Non-diabetic mice    
 Control  6.43±0.32 6.18±0.25 6.10±0.10 
Irbesartan 20 mg/kg  6.42±0.22 6.77±0.13 5.9±0.21 
Irbesartan 75 mg/kg  6.47±0.20 6.77±0.48 6.32±0.22 
Diabetic mice     
Negative Control  13.85±3.01 11.25±2.15 12.23±2.58 
Irbesartan 20 mg/kg  14.98±2.07 12.80±2.69 9.34±2.48 
Irbesartan 75 mg/kg  14.30±2.66 11.25±2.29 9.42±2.58 
 
Effect of irbesartan on blood glucose levels in non-
diabetic mice 
Figures 1 and 2 show the percentage change from 
baseline in blood glucose levels in non-diabetic mice on 
day 8 and day 13, respectively. On day 8, only the 
control group had a decrease in blood glucose (Mean= -
3.62%; SEM=1.18). The other treatment groups showed 
an increase in blood glucose levels: 20mg/kg (Mean= 
+6.20%;SEM=4.76), and 75mg/kg (Mean=+5.39%; 
SEM=8.78). There was no significant difference in the 
change in blood glucose levels on day 8 in non-diabetic 
mice that were administered 20mg/kg irbesartan, 
75mg/kg irbesartan, and control group (F=0.8819; 
d.f.=2;15; p=0.4344). On day 13, all the three groups had 
reduced blood glucose values. The group administered 
20mg/kg irbesartan had the greatest change in blood 
glucose levels (Mean= -14.87%; SEM=10.13), followed 
by the group administered 75mg/kg irbesartan (Mean= 
-9.06%; SEM=3.77) with the control group showing the 
least change (Mean= -7.33%; SE=1.77). However, there 
was no significant difference in the change in blood 
glucose levels between mice that were administered 
20mg/kg irbesartan, 75mg/kg irbesartan, and the 
control group (F=0.6900; d.f.=2;15; p=0.6837). 
Effect of irbesartan on blood glucose levels in 
diabetic mice  
Figure 3 shows the percentage change in blood glucose 
levels in diabetic mice after 8 days of drug 
administration. All the groups showed a decrease in 
blood glucose levels with the group administered 
75mg/kg irbesartan (Mean= -22.19%; SEM=4.65) 
showing the highest decrease followed by the positive 
control (P/control) group (Mean= -16.99%; SEM=3.10). 
There was no significant difference in the blood glucose 
changes between the 20mg/kg irbesartan group, 
75mg/kg irbesartan group, and the P/control group 
(F=1.240; d.f.=2;14; p=0.3245).  
Figure 4 shows the percentage change in blood glucose 
levels in diabetic mice after 13 days of drug 
administration. All the groups showed a decrease in 
blood glucose levels with the group administered 
75mg/kg irbesartan showing the highest decrease 
(Mean= -40.07%; SEM=6.27). The P/control group 
showed the least decrease (Mean= -11.36; SEM=1.59). 
There was a significant difference in the change in blood 
glucose levels between diabetic mice that were 
administered 20mg/kg irbesartan, 75mg/kg irbesartan, 
and the P/control group (F=7.674; d.f. =2;14; 
p=0.0056).  
A Bonferroni post-hoc test showed that the decrease in 
blood glucose levels was higher in the 20mg/kg 
irbesartan group (-39.44%) than in the P/control group 
(-11.36%) (p =0.0177). There was also a significant 
difference in the change in blood glucose levels in 
diabetic mice that were administered 75mg/kg 
irbesartan (-40.07%) compared to P/control group (-
11.36%) (p =0.0111). 
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Figure 1: Percentage change in blood glucose from baseline 
to day 8 in non-diabetic mice; Data are expressed as the mean 
± SEM 
 Figure 2: Percentage change in blood glucose from baseline 
to day 13 in non-diabetic mice; Data are expressed as the 













Figure 3: Percentage change in blood glucose from baseline 
to day 8 in diabetic mice; Data are expressed as the mean ± 
SEM 
 Figure 4: Percentage change in blood glucose from baseline 





Figure 5: Effect of irbesartan on oral glucose tolerance in 
non-diabetic mice; Data are expressed as mean ± SEM 
 Figure 6: Effect of irbesartan on oral glucose tolerance in 
diabetic mice; Data are expressed as mean ± SEM 
   
Effect of irbesartan on glucose tolerance in both 
diabetic and non-diabetic mice 
Figure 5 and 6 show the area under the curve (AUC) 
obtained during the OGTT in non-diabetic and diabetic 
mice, respectively. In non-diabetic mice, the AUCs of the 
different treatment groups were almost similar, 
20mg/kg irbesartan group (Mean=28.73mmol/L; 
SEM=0.52), 75mg/kg irbesartan group 
(Mean=26.66mmol/L; SEM=0.74) and Control 
(Mean=27.24mmol/L; SEM=1.07). 
There was no significant difference in the glucose 
tolerance across the three treatment groups (F=1.734; 
d.f.=2;15; p=0.2102).In diabetic mice, the 75mg/kg 
irbesartan group had the lowest AUC 
(Mean=45.54mmol/L; SEM=5.81) reflecting an 
improvement in glucose tolerance compared to the 
P/control group (Mean=63.43mmol/L; SEM=4.44). The 
AUC of the 20mg/kg irbesartan group was also lower 
than the P/control group reflection of a possible 
improvement in glucose tolerance 
(Mean=55.35mmol/L; SEM=8.78).  
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However, there was no significant difference in the 
glucose tolerance across the three treatment groups 
(F=2.139; d.f.=2;14; p=0.1547). 
4. Discussion 
Analysis of blood glucose levels in non-diabetic mice 
after eight days and 13 days of treatment in all the three 
groups (20mg/kg and 75mg/kg irbesartan and control) 
did not show any significant changes or decreases. 
These findings are consistent with a study by Onishi et 
al., who observed that irbesartan at doses of 50mg and 
100mg in haemodialysis hypertensive patients does not 
cause any significant changes in blood glucose levels 
(Onishi et al, 2013). Similarly, Maeda et al., concluded 
that irbesartan at 50mg/kg does not cause any 
significant changes in blood glucose levels in non-
diabetic mice (Maeda et al, 2014). The findings in the 
present study give further evidence on the safety of 
irbesartan in non-diabetic hypertensive patients. In the 
diabetic mice, the pattern of blood glucose level changes 
was different from that observed in the non-diabetic 
mice. The 20mg/kg and 75mg/kg irbesartan doses 
decreased blood glucose significantly compared to the 
control group on day 13. The changes in blood glucose 
levels were consistent with findings from a study by 
Henriksen et al., who observed that 25mg/kg and 
50mg/kg irbesartan significantly lowers blood glucose 
levels in obese Zucker rats (Henriksen et al, 2001). 
Irbesartan was also shown to reduce blood glucose in 
diabetic rats partly by increased insulin secretion as a 
result of increased blood flow to the pancreas (Huang et 
al, 2006). On day eight however, in the non-diabetic 
mice, there was a slight increase in blood glucose levels 
in the 20mg/kg and 75mg/kg irbesartan groups, 
possibly as a result of stress related stimulation of the 
sympathetic nervous system (Surwit. et al, 1992). 
The effect of irbesartan on glucose tolerance in non-
diabetic mice was also evaluated in this study using the 
oral glucose tolerance test. Similar to the blood glucose 
level analysis on day 8 and day 13 in the non-diabetic 
mice, the OGTT in all the three groups did not show any 
significant differences. This is suggestive of irbesartan 
not having any significant effects on blood glucose 
levels, glucose tolerance and insulin sensitivity in non-
diabetic animals. In diabetic mice, both doses of 
irbesartan in diabetic mice did not significantly improve 
the glucose tolerance compared to the control group. 
Although there was no statistical difference between 
the two doses of irbesartan, there was generally an 
improvement in glucose tolerance compared to the 
control group. The findings of the present study were 
not consistent with the findings by Henriksen et al. 
(2001) who reported that the 50mg/kg irbesartan 
administered for 21 days to diabetic obese Zucker rats 
improves glucose tolerance as evidenced by 
significantly lower AUCs compared to control obese 
diabetic Zucker rats (Henriksen et al, 2001).The lack of 
significant improvement in glucose tolerance in the 
current study might be explained by a shorter 
irbesartan treatment period. 
From the findings in this study the use of irbesartan in 
co-morbid diabetes and hypertension should be 
encouraged because of its potential positive effects on 
glycaemic control. However, blood glucose levels should 
be measured regularly for those diabetic patients using 
antidiabetic agents and irbesartan since irbesartan 
theoretically would augment their hypoglycaemic 
effects. The present study forms a basis for further 
research on animals to confirm the mechanism by 
which irbesartan reduces blood glucose levels 
significantly in diabetic mice and not in non-diabetic 
mice. The study also forms the basis for further 
research into the pharmacodynamic interactions of 
irbesartan and commonly prescribed antidiabetic 
agents first in animals then in humans. 
5. Conclusion 
In the present study, irbesartan significantly reduced 
blood glucose levels in diabetic mice and not in non-
diabetic mice. However, a two week treatment with 
irbesartan did not significantly improve glucose 
tolerance in both diabetic and non-diabetic mice. 
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